Securities code: 002932 securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022-002 Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
The trading price of Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) (hereinafter referred to as “the company”) (securities code “002932”, securities abbreviation ” Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) “) has deviated from the closing price for two consecutive trading days (January 7, 2022 and January 10, 2022) by more than 20% in total. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Description of concerns and verification on important issues
In view of the abnormal fluctuation of the company’s shares, the company has checked relevant matters and asked the controlling shareholder and actual controller of the company. The relevant information is described as follows:
(I) the company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
(II) there has been no significant change in the company’s business situation and internal and external business environment recently;
(III) it is verified that the company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or are in the planning stage;
(IV) after verification, Mr. Wang Rui, deputy general manager and Secretary of the board of directors of the actual controller of the company, and Xinyu chenheng investment partnership (limited partnership) jointly reduced 350500 shares of the company on January 10, 2022. The details are as follows: Mr. Wang Ruisheng:
Name of shareholder: Wang Rui
Number of shares of the company held at the end of last year (shares) 1601567
Transaction period: January 10, 2022
Reduction mode: centralized bidding
Transaction price (yuan / share): 89.31 yuan / share – 92.31 yuan / share
Number of transactions (shares) 133500
Number of shares held before this change (shares) 1601567
Number of shares held after this change (shares) 1468067
Xinyu chenheng investment partnership (limited partnership):
Name of shareholder: Xinyu chenheng investment partnership (limited partnership)
Number of shares of the company held at the end of last year (shares) 2656420
Transaction period: January 10, 2022
Reduction mode: centralized bidding
Transaction price (yuan / share): 92.29 yuan / share – 92.31 yuan / share
Transaction volume (shares) 177000
Block trading by way of reduction
Transaction price (yuan / share) 77.21
Transaction volume (shares) 40000
Number of shares held before this change (shares) 2656420
Number of shares held after this change (shares) 2439420
Except for the above changes in shares, the controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the period of stock change;
(V) through self-examination, the data in Item 2, Section III of the report on changes in equity disclosed by the company on December 12, 2021 were calculated incorrectly. The specific corrections are as follows:
Before correction:
On October 9, 2020, after the company issued 2.42 million A-share common shares and restricted shares to the incentive objects, the total number of shares of the company increased from 66585147 to 69005147. The controlling shareholder Chen Lili and its concerted actors Wang Ying, Wang Rui and Xinyu chenheng passively diluted their shareholding ratio by 1.84% without any change in the shareholding number.
After correction:
On October 9, 2020, the company issued 2.42 million A-share common shares and 69005147 shares to the incentive objects. After listing, the total number of shares of the company increased from 66585147 shares to 69005147 shares. The company granted 300000 restricted shares to Mr. Wang Rui, deputy general manager and Secretary of the board of directors. Chen Lili, the controlling shareholder of the company, and Wang Ying, Wang Rui and Xinyu chenheng, who acted in concert, The shareholding ratio was diluted by 1.39%.
In addition to the above corrections, there is no need to correct or supplement other disclosed information;
(VI) through self-examination, the company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of information that should be disclosed but not disclosed
No matters related to the company’s intention to disclose, plan or negotiate with the Shenzhen Stock Exchange in accordance with the provisions of the Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; In addition to the above corrections, there is no need to correct or supplement other disclosed information. 4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions;
2. Since the fourth quarter of 2021, affected by the epidemic situation of delta and Omicron, covid-19 infection cases in Europe, Southeast Asia and other countries and regions have continued to repeat and remain high, resulting in increased demand for covid-19 antigen detection reagent and nucleic acid detection reagent, and the company’s foreign trade orders and related income of overseas covid-19 detection reagent have increased significantly.
3. Since the repeated infection cases of covid-19 epidemic in many places in China in December 2021, Shaanxi, Henan and other places have started full nucleic acid detection. As a supplier of covid-19 nucleic acid testing reagents and a third-party testing service provider of covid-19 nucleic acid testing, the company is always ready to provide testing products and testing services for epidemic areas. Up to now, the company has quickly established a professional medical testing team, ready to rush to Henan and other regions. In addition, the company will fully mobilize production and inventory to fully ensure the supply of covid-19 nucleic acid detection related products.
At present, the company is unable to predict the specific impact of the above matters on the company’s performance. In the future, with the epidemic gradually controlled, the demand for relevant covid-19 testing products and services is expected to be unsustainable. The company reminds investors to fully understand the stock market risks, pay special attention to the risk factors disclosed in the company’s periodic reports and other disclosed documents, make rational investment and make prudent decisions.
4. At this stage, the company is in the period of preparing the periodic report. The company has disclosed the annual performance forecast for 2021 on January 5, 2022. It is expected that the net profit attributable to the shareholders of the listed company in 2021 will be RMB 130 million-150 million, an increase of 177.23% – 219.88% over the same period of the previous year. Prior to the disclosure of this announcement, the company’s undisclosed periodic performance information was not provided to a third party other than the accounting firm audited by the company; The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The company shall not amend the annual performance forecast for 2021.
5. The board of directors of the company solemnly reminds investors that the information disclosure media designated by the company are securities times, China Securities News and cninfo（ http://www.cn.info.com.cn. ）, all information disclosure of the company shall be subject to the announcement published in the above media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) board of directors
January 11, 2022
